Sanofi Stumps Up $125m To Access Denali RIPK1 Inhibitors
Executive Summary
The French drugmaker is dipping its toe into Alzheimer's disease as part of a CNS and inflammatory alliance with Denali which could net the US firm $1bn on top of a hefty upfront fee.
You may also be interested in...
Sanofi, Denali Drug Fails In ALS, Adding To RIPK1 Program Setbacks
The companies have partnered on the development of RIPK1 inhibitors for multiple indications since 2018, but have yet to see success, having discontinued one of three drugs already.
Biogen Builds Out Parkinson's Pipeline With Denali Deal
Biogen will pay Denali $560m up front plus a $465m equity investment in exchange for co-development and co-commercialization rights to clinical-stage LRRK2 inhibitors for Parkinson's disease.
Finance Watch: Billions Of Dollars In Offerings Despite US Biopharma Stock Slump
Blueprint and Zymeworks raise $300m-plus in follow-on offerings. Also, Arcutis, Black Diamond and Annovis bring the 2020 US IPO count to four; Spring Bank, Surface Oncology and Decibel reveal strategic shifts; and Harmony’s $200m in venture debt leads recent VC deals.